Learn more

THERION BIOLOG CORP

Overview
  • Total Patents
    51
About

THERION BIOLOG CORP has a total of 51 patent applications. Its first patent ever was published in 1988. It filed its patents most often in United States, Canada and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets biotechnology, pharmaceuticals and machines are CANJI INC, OKAIROS AG and BEIJING FIVEPLUS MOLECULAR MEDICINE INST CO LTD.

Patent filings in countries

World map showing THERION BIOLOG CORPs patent filings in countries
# Country Total Patents
#1 United States 14
#2 Canada 10
#3 WIPO (World Intellectual Property Organization) 10
#4 Australia 7
#5 EPO (European Patent Office) 6
#6 Japan 4

Patent filings per year

Chart showing THERION BIOLOG CORPs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Panicali Dennis L 35
#2 Schlom Jeffrey 21
#3 Gritz Linda R 20
#4 Mazzara Gail P 13
#5 Panicali Dennis 10
#6 Rosenberg Steven A 10
#7 Gritz Linda 5
#8 Roberts Bryan 4
#9 Stallard Virginia 4
#10 Payne Lendon 4

Latest patents

Publication Filing date Title
CA2515890A1 Novel insertion sites in pox vectors
US2004101522A1 Transduced neoplastic cell preparations able to express T-cell costimulatory molecules B7.1, ICAM-1, and LFA-3 and induce immunostimulatory prophylactic and therapeutic anti-tumor effects in-vivo
AU5419401A Recombinant pox virus for immunization against tumor-associated antigens
CA2282300A1 Recombinant pox virus for immunization against muc1 tumor-associated antigen
EP0954593A1 Recombinant pox virus for immunization against tumor-associated antigens
WO9804728A1 Recombinant pox virus for immunization against tumor-associated antigens
AU2658697A Recombinant pox virus encoding myelin protein for therapy
US6165460A Generation of immune responses to prostate-specific antigen (PSA)
US6699475B1 Recombinant pox virus for immunization against tumor-associated antigens
US5804196A Self assembled, defective, nonself-propagating viral particles
US6001349A Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
US5656465A Methods of in vivo gene delivery
US5747324A Self-assembled, defective, non-self-propagating lentivirus particles
WO9203537A1 Self-assembling replication defective hybrid virus particles
US5242829A Recombinant pseudorabies virus
US5093258A Recombinant fowlpox virus and recombination vector